Membrane transporters as determinants of the pharmacology of platinum anticancer drugs

Current Cancer Drug Targets

Volumn 12, Issue 8, 2012, Pages 962-986

  Liu, Johnson J ^a   Lu, Jun ^b   McKeage, Mark J ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b AUCKLAND UNIVERSITY OF TECHNOLOGY   (New Zealand)

Author keywords

ABC transporter; Membrane transporter; Platinum resistance; Platinum toxicity; Platinum based anticancer drug; Solute carrier transporter

Indexed keywords

ABC TRANSPORTER; ADENOSINE TRIPHOSPHATASE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CARRIER PROTEIN; CISPLATIN; MEMBRANE PROTEIN; ORGANIC CATION TRANSPORTER; OXALIPLATIN; PICOPLATIN; PLATINUM;

ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER CHEMOTHERAPY; HUMAN; MEMBRANE TRANSPORT; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; OTOTOXICITY; PROTEIN EXPRESSION; REVIEW; TUMOR RESISTANCE;

ADENOSINE TRIPHOSPHATASES; ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CATION TRANSPORT PROTEINS; CISPLATIN; HUMANS; MEMBRANE TRANSPORT PROTEINS; NEOPLASMS; PLATINUM; PLATINUM COMPOUNDS; TREATMENT OUTCOME;

EID: 84867808638     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/156800912803251199     Document Type: Review

References (203)

1. Vasiliou, V.; Vasiliou, K.; Nebert, D. W. Human ATP-binding cassette (ABC) transporter family. Hum. Genomics 2009, 3, 281-290.
2. He, L.; Vasiliou, K.; Nebert, D. W. Analysis and update of the human solute carrier (SLC) gene superfamily. Hum. Genomics 2009, 3, 195-206.
3. Venter, J. C.; Adams, M. D.; Myers, E. W.; Li, P. W.; Mural, R. J.; Sutton, G. G.; Smith, H. O.; Yandell, M.; Evans, C. A.; Holt, R. A.; Gocayne, J. D.; et al. The sequence of the human genome. Science 2001, 291, 1304-1351.
4. Saier, M. H.; Yen, M. R.; Noto, K.; Tamang, D. G.; EIkan, C. The transporter classification database: recent advances. Nucl. Acids Res. 2009, 37, D274-D278.
5. DeGorter, M. K.; Xia, C. Q.; Yang, J. J.; Kim, R. B. Drug transporters in drug efficacy and toxicity. Annu. Rev. Pharmacol. Toxicol. 2012, 52, 249-273.
6. Zolk, O.; Fromm, M. F. Transporter-mediated drug uptake and efflux: important determinants of adverse drug reactions. Clin. Pharmacol. Therap. 2011, 89, 798-805.
7. Dobson, P. D.; Kell, D. B. Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule? Nat. Rev. Drug Disc. 2008, 7, 205-220.
8. Sai, Y. Biochemical and molecular pharmacological aspects of transporters as determinants of drug disposition. Drug Metab. Pharmacokinet. 2005, 20, 91-99.
9. Hediger, M. A.; Romero, M. F.; Peng, J. B.; Rolfs, A.; Takanaga, H.; Bruford, E. A. The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteins. Pflug. Arch. 2004, 447, 465-468.
10. Choudhuri, S.; Klaassen, C. D. Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Intl. J. Toxicol. 2006, 25, 231-259.
11. Gottesman, M. M.; Fojo, T.; Bates, S. E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2002, 2, 48-58.
12. Huang, Y.; Sadee, W. Membrane transporters ans channels in chemoresistance and-sensitivity of tumor cells. Cancer Lett. 2006, 239, 168-182.
13. Bajorin, D. F.; Sarosdy, M. F.; Pfister, D. G.; Mazumdar, M.; Motzer, R. J.; Scher, H. I.; Geller, N. L.; Fair, W. R.; Herr, H.; Sogani, P.; Sheinfeld, J.; Russo, P.; Vlamis, V.; Carey, R.; Vogelzang, N. J.; Crawford, E. D.; Bosl, G. J. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ-cell tumors-a multiinstitutional study. J. Clin. Oncol. 1993, 11, 598-606.
14. Trimbos, J. B.; Parmar, M.; Vergote, I.; Guthrie, D.; Bolis, G.; Colombo, N.; Vermorken, J. B.; Torri, V.; Mangioni, C.; Pecorelli, S.; Lissoni, A.; Swart, A.M. International collaborative ovarian neoplasm trial 1 and adjuvant chemotherapy in ovarian neoplasm trial: Two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J. Natl. Cancer. Inst. 2003, 95, 105-112.
15. Ardizzoni, A.; Boni, L.; Tiseo, M.; Fossella, F. V.; Schiller, J. H.; Paesmans, M.; Radosavljevic, D.; Paccagnella, A.; Zatloukal, P.; Mazzanti, P.; Bisset, D.; Rosell, R. Cisplatin-versus carboplatinbased chemotherapy in first-line treatment of advanced non-smallcell lung cancer: An individual patient data meta-analysis. J. Natl. Cancer Inst. 2007, 99, 847-857.
16. de Gramont, A.; Figer, A.; Seymour, M.; Homerin, M.; Hmissi, A.; Cassidy, J.; Boni, C.; Cortes-Funes, H.; Cervantes, A.; Freyer, G.; Papamichael, D.; Le Bail, N.; Louvet, C.; Hendler, D.; de Braud, F.; Wilson, C.; Morvan, F.; Bonetti, A. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 2000, 18, 2938-2947.
17. Rosenberg, J.E.; Carroll, P.R.; Small, E.J. Update on chemotherapy for advanced bladder cancer. J. Urol. 2005, 174, 14-20.
18. Bhide, S.A.; Nutting, C.M. Advances in chemotherapy for head and neck cancer. Oral Oncol. 2010, 46, 436-438.
19. Wernyj, R.P.; Morin, P.J. Molecular mechanisms of platinum resistance: still searching for the Achilles' heel. Drug Resist. Update 2004, 7, 227-232.
20. Grothey, A. Oxaliplatin-safety profile: neurotoxicity. Semin. Oncol. 2003, 30, 5-13.
21. Koga, H.; Kotoh, S.; Nakashima, M.; Yokomizo, A.; Tanaka, M.; Naito, S. Accumulation of intracellular platinum is correlated with intrinsic cisplatin resistance in human bladder cancer cell lines. Int. J. Oncol. 2000, 16, 1003-1007.
22. Hector, S.; Bolanowska-Higdon, W.; Zdanowicz, J.; Hitt, S.; Pendyala, L. In vitro studies on the mechanisms of oxaliplatin resistance. Cancer Chemother. Pharmacol. 2001, 48, 398-406.
23. Shen, D. W.; Goldenberg, S.; Pastan, I.; Gottesman, M. M. Decreased accumulation of [14C]carboplatin in human cisplatinresistant cells results from reduced energy-dependent uptake. J. Cell Physiol. 2000, 183, 108-116.
24. Holford, J.; Beale, P. J.; Boxall, F. E.; Sharp, S. Y.; Kelland, L. R. Mechanisms of drug resistance to the platinum complex ZD0473 in ovarian cancer cell lines. Eur. J. Cancer 2000, 36, 1984-1990.
25. Stewart, D. J.; Mikhael, N. Z.; Nair, R. C.; Kacew, S.; Montpetit, V.; Nanji, A.; Maroun, J. A.; Howard, K. Platinum concentrations in human autopsy tumor samples. Am. J. Clin. Oncol. 1988, 11, 152-158.
26. Wang, D.; Lippard, S. J. Cellular processing of platinum anticancer drugs. Nat. Rev. Drug. Discov. 2005, 4, 307-320.
27. Hall, M. D.; Okabe, M.; Shen, D. W.; Liang, X. J.; Gottesman, M. M. The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu. Rev. Pharmacol. Toxicol. 2008, 48, 495-535.
28. Krarup-Hansen, A.; Rietz, B.; Krarup, C.; Heydorn, K.; Rørth, M.; Schmalbruch, H. Histology and platinum content of sensory ganglia and sural nerves in patients treated with cisplatin and carboplatin: an autopsy study. Neuropathol. Appl. Neurobiol. 1999, 25, 29-40.
29. Screnci, D.; McKeage, M. J.; Galettis, P.; Hambley, T. W.; Palmer, B. D.; Baguley, B. C. Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs. Br. J. Cancer 2000, 82, 966-972.
30. Pabla, N.; Dong, Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Intl. 2008, 73, 994-1007.
31. Rybak, L. P.; Mukherjea, D.; Jajoo, S.; Ramkumar, V. Cisplatin ototoxicity and protection: clinical and experimental studies. Tohoku. J. Exp. Med. 2009, 219, 177-186.
32. More, S. S.; Akil, O.; Ianculescu, A. G.; Geier, E. G.; Lustig, L. R.; Giacomini, K. M. Role of the copper transporter, CTR1, in platinum-induced ototoxicity. J. Neurosci. 2010, 30, 9500-9509.
33. Burger, H.; Loos, W. J.; Eechoute, K.; Verweij, J.; Mathijssen, R. H.; Wiemer, E. A. C. Drug transporters of platinum-based anticancer agents and their clinical significance. Drug Resist. Update 2011, 14, 22-34.
34. Gately, D.P.; Howell, S.B. Cellular accumulation of the anticancer agent cisplatin: a review. Br. J. Cancer 1993, 67, 1171-1176.
35. Kawabe, T.; Chen, Z. S.; Wada, M.; Uchiumi, T.; Ono, M.; Akiyama, S. I.; Kuwano, M. Enhanced transport of anticancer agents and leukotriene C4 by the human canalicular multispecific organic anion transporter (cMOAT/MRP2). FEBS Lett. 1999, 456, 327-331.
36. Cui, Y. H.; Konig, J.; Buchholz, U.; Spring, H.; Leier, I.; Keppler, D. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol. Pharmacol. 1999, 55, 929-937.
37. Koike, K.; Kawabe, T.; Tanaka, T.; Toh, S.; Uchiumi, T.; Wada, M.; Akiyama, S. I.; Ono, M.; Kuwano, M. A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells. Cancer Res. 1997, 57, 5475-5479.
38. Materna, V.; Liedert, B.; Thomale, J.; Lage, H. Protection of platinum-DNA adduct formation and reversal of cisplatin resistance by anti-MRP2 hammerhead ribozymes in human cancer cells. Intl. J. Cancer 2005, 115, 393-402.
39. Materna, V.; Stege, A.; Surowiak, P.; Priebsch, A.; Lage, H. RNA interference-triggered reversal of ABCC2-dependent cisplatin resistance in human cancer cells. Biochem. Biophys. Res. Commun. 2006, 348, 153-157.
40. Folmer, Y.; Schneider, M.; Blum, H. E.; Hafkemeyer, P. Reversal of drug resistance of hepatocellular carcinoma cells by adenoviral delivery of anti-ABCC2 antisense constructs. Cancer Gene Ther. 2007, 14, 875-884.
41. Ma, J. J.; Chen, B. L.; Xin, X. Y. Inhibition of multi-drug resistance of ovarian carcinoma by small interfering RNA targeting to MRP2 gene. Arch. Gynecol. Obstet. 2009, 279, 149-157.
42. Xie, S. M.; Fang, W. Y.; Liu, Z.; Wang, S. X.; Li, X.; Liu, T. F.; Xie, W. B.; Yao, K. T. Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin. J. Transl. Med. 2008, 6, 55.
43. Guminski, A. D.; Balleine, R. L.; Chiew, Y. E.; Webster, L. R.; Tapner, M.; Farrell, G. C.; Harnett, P. R.; deFazio, A. MRP2 (ABCC2) and cisplatin sensitivity in hepatocytes and human ovarian carcinoma. Gynecol. Oncol. 2006, 100, 239-246.
44. Beretta, G. L.; Benedetti, V.; Cossa, G.; Assaraf, Y. G. A.; Bram, E.; Gatti, L.; Corna, E.; Carenini, N.; Colangelo, D.; Howell, S. B.; Zunino, F.; Perego, P. Increased levels and defective glycosylation of MRPs in ovarian carcinoma cells resistant to oxaliplatin. Biochem. Pharmacol. 2010, 79, 1108-1117.
45. Ishida, S.; Lee, J.; Thiele, D. J.; Herskowitz, I. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc. Natl. Acad. Sci. USA 2002, 99, 14298-14302.
46. Lin, X.; Okuda, T.; Holzer, A.; Howell, S. B. The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae. Mol. Pharmacol. 2002, 62, 1154-1159.
47. Sinani, D.; Adle, D. J.; Kim, H.; Lee, J. Distinct mechanisms for Ctr1-mediated copper and cisplatin transport. J. Biol. Chem. 2007, 282, 26775-26785.
48. Samimi, G.; Howell, S.B. Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters. Cancer Chemother. Pharmacol. 2006, 57, 781-788.
49. Holzer, A. K.; Manorek, G. H.; Howell, S. B. Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin. Mol. Pharmacol. 2006, 70, 1390-1394.
50. Larson, C. A.; Balir, B. G.; Safaei, R.; Howell, S. B. The role of the mammalian copper transporter 1 in the cellular accumulation of platinum-based drugs. Mol. Pharmacol. 2009, 75, 324-330.
51. Ishida, S.; McCormick, F.; Smith-McCune, K.; Hanahan, D. Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator. Cancer Cell 2010, 17, 574-583.
52. Pabla, N.; Murphy, R. F.; Liu, K.; Dong, Z. The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. Am. J. Physiol. Renal Physiol. 2009, 296, F505-F511.
53. Holzer, A. K.; Samimi, G.; Katano, K.; Naerdemann, W.; Lin, X.; Safaei, R.; Howell, S. B. The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells. Mol. Pharmacol. 2004, 66, 817-823.
54. Kabolizadeh, P.; Ryan, J.; Farrell, N. Differences in the cellular response and signaling pathways of cisplatin and BBR3464 ([{trans-PtCl(NH3)(2)}(2)mu-(trans-Pt(NH3)(2)(H2N(CH2)(6)-NH2)(2)](4+) influenced by copper homeostasis. Biochem. Pharmacol. 2007, 73, 1270-1279.
55. Song, I. S.; Savaraj, N.; Siddik, Z. H.; Liu, P.; Wei, Y.; Wu, C. J.; Kuo, M. T. Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells. Mol. Cancer Ther. 2004, 3, 1543-1549.
56. Liang, Z. D.; Stockton, D.; Savaraj, N.; Kuo, M. T. Mechanistic comparison of human high-affinity copper transporter 1-mediated transport between copper ion and cisplatin. Mol. Pharmacol. 2009, 76, 843-853.
57. Larson, C. A.; Adams, P. L.; Blair, B. G.; Safaei, R.; Howell, S. B. The role of the methionines and histidines in the transmembrane domain of mammalian copper transporter 1 in the cellular accumulation of cisplatin. Mol. Pharmacol. 2010, 78, 333-339.
58. Larson, C. A.; Adams, P. L.; Jandial, D. D.; Blair, B. G.; Safaei, R.; Howell, S. B. The role of the N-terminus of mammalian copper transporter 1 in the cellular accumulation of cisplatin. Biochem. Pharmacol. 2010, 80, 448-454.
59. Blair, B. G.; Larson, C.; Safaei, R.; Howell, S. B. Copper transporter 2 regulates the cellular accumulation and cytotoxicity of cisplatin and carboplatin. Clin. Cancer Res. 2009, 15, 4312-4321.
60. Komatsu, M.; Sumizawa, T.; Mutoh, M.; Chen, Z. S.; Terada, K.; Furukawa, T.; Yang, X. L.; Gao, H.; Miura, N.; Sugiyama, T.; Akiyama, S. Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance. Cancer Res. 2000, 60, 1312-1316.
61. Katano, K.; Safaei, R.; Samimi, G.; Holzer, A.; Rochdi, M.; Howell, S. B. The copper export pump ATP7B modulates the cellular pharmacology of carboplatin in ovarian carcinoma cells. Mol. Pharmacol. 2003, 64, 466-473.
62. Mangala, L. S.; Zuzel, V.; Schmandt, R.; Leshane, E. S.; Haider, J. B.; Armaiz-Pena, G. N.; Spannuth, W. A.; Tanaka, T.; Shahzad, M. M. K.; Lin, Y. G.; Nick, A. M.; Danes, C. G.; Lee, J. W.; Jennings, N. B.; Vivas-Mejia, P. E.; Wolf, J. K.; Coleman, R. L.; Siddik, Z. H.; Lopez-Berestein, G.; Lutsenko, S.; Sood, A. K. Therapeutic targeting of ATP7B in ovarian carcinoma. Clin. Cancer Res. 2009, 15, 3770-3780.
63. Samimi, G.; Katano, K.; Holzer, A. K.; Safaei, R.; Howell, S. B. Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B. Mol. Pharmacol. 2004, 66, 25-32.
64. Rabik, C. A.; Maryon, E. B.; Kasza, K.; Shafer, J. T.; Bartnik, C. M.; Dolan, M. E. Role of copper transporters in resistance to platinating agents. Cancer Chemother. Pharmacol. 2009, 64, 133-142.
65. Samimi, G.; Safaei, R.; Katano, K.; Holzer, A. K.; Rochdi, M.; Tomioka, M.; Goodman, M.; Howell, S. B. Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells. Clin. Cancer Res. 2004, 10, 4661-4669.
66. Chen, C.; Chen, L.; Tsou, T. Combined modalities of resistance in an oxaliplatin-resistant human gastric cancer cell line with enhanced sensitivity to 5-fluorouracil. Bri. J. Cancer 2007, 97, 334-344.
67. Owatari, S.; Akune, S.; Komatsu, M.; Ikeda, R.; Firth, S. D.; Che, X. F.; Yamamoto, M.; Tsujikawa, K.; Kitazono, M.; Ishizawa, T.; Takeuchi, T.; Aikou, T.; Mercer, J. F. B.; Akiyama, S.; Furukawa, T. Copper-transporting P-type ATPase, ATP7A, confers multidrug resistance and its expression is related to resistance to SN-38 in clinical colon cancer. Cancer Res. 2007, 67, 4860-4868.
68. More, S. S.; Li, S. L.; Yee, S. W.; Chen, L. G.; Xu, Z. D.; Jablons, D. M.; Giacomini, K. M. Organic cation transporters modulate the uptake and cytotoxicity of picoplatin, a third-generation platinum analogue. Mol. Cancer Ther. 2010, 9, 1058-1069.
69. Zhang, S.; Lovejoy, K. S.; Shima, J. E.; Lagpacan, L. L.; Shu, Y.; Lapuk, A.; Chen, Y.; Komori, T.; Gray, J. W.; Chen, X.; Lippard, S. J.; Giacomini, K. M. Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006, 66, 8847-8857.
70. Lovejoy, K. S.; Todd, R. C.; Zhang, S. Z.; McCormick, M. S.; D'Aquino, J. A.; Reardon, J. T.; Sancar, A.; Giacomini, K. M.; Lippard, S. J. cis-diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II) antitumor agent: uptake, structure, function, and prospects. Proc. Natl. Acad. Sci. USA 2008, 105, 8902-8907.
71. Yonezawa, A.; Masuda, S.; Yokoo, S.; Katsura, T.; Inui, K. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J. Pharmacol. Exp. Ther. 2006, 319, 879-886.
72. Tanihara, Y.; Masuda, S.; Katsura, T.; Inui, K. Protective effect of concomitant administration of imatinib on cisplatin-induced nephrotoxicity focusing on renal organic cation transporter OCT2. Biochem. Pharmacol. 2009, 78, 1263-1271.
73. Li, S. L.; Chen, Y.; Zhang, S. Z.; More, S. S.; Huang, X. Z.; Giacomini, K. M. Role of organic cation transporter 1, OCT1 in the pharmacokinetics and toxicity of cis-diammine(pyridine) chloroplatinum(II) and oxaliplatin in mice. Pharmaceut. Res. 2011, 28, 610-625.
74. Nakamura, T.; Yonezawa, A.; Hashimoto, S.; Katsura, T.; Inui, K. Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity. Biochem. Pharmacol. 2010, 80, 1762-1767.
75. Ciarimboli, G.; Ludwig, T.; Lang, D. F.; Pavenstadt, H.; Koepsell, H.; Piechota, H. J.; Haier, J.; Jaehde, U.; Zisowsky, J.; Schlatter, E. Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am. J. Pathol. 2005, 167, 1477-1484.
76. Filipski, K. K.; Loos, W. J.; Verweij, J.; Sparreboom, A. Interaction of cisplatin with the human organic cation transporter 2. Clin. Cancer Res. 2008, 14, 3875-3880.
77. Yokoo, S.; Yonezawa, A.; Masuda, S.; Fukatsu, A.; Katsura, T.; Inui, K. I. Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity. Biochem. Pharmacol. 2007, 74, 477-487.
78. Yonezawa, A.; Masuda, S.; Nishihara, K.; Yano, I.; Katsura, T.; Inui, K. Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat. Biochem. Pharmacol. 2005, 70, 1823-1831.
79. Yokoo, S.; Masuda, S.; Yonezawa, A.; Terada, T.; Katsura, T.; Inui, K. I. Significance of organic cation transporter 3 (SLC22A3) expression for the cytotoxic effect of oxaliplatin in colorectal cancer. Drug Metab. Dispos. 2008, 36, 2299-2306.
80. Li, Q.; Peng, X.; Tang, H.; Rodriguez, J.; Shu, Y. Contribution of organic cation transporter 3 to cisplatin cytotoxicity in human cervical cancer cells. J. Pharm. Sci. 2012, 101, 394-404.
81. Jong, N. N.; Nakanishi, T.; Liu, J. J.; Tamai, I.; McKeage, M. J. Oxaliplatin transport mediated by organic cation/carnitine transporters OCTN1 and OCTN2 in over-expressing HEK293 cells and rat dorsal root ganglion neurons. J. Pharmacol. Exp. Ther. 2011, 338, 537-547.
82. Nies, A. T.; Keppler, D. The apical conjugate efflux pump ABCC2 (MRP2). Pflug. Arch. 2007, 453, 643-659.
83. Grant, C. E.; Kurz, E. U.; Cole, S. P. C.; Deeley, R. G. Analysis of the intron-exon organization of the human multidrug-resistance protein gene (MRP) and alternative splicing of its mRNA. Genomics 1997, 45, 368-378.
84. Deeley, R. G.; Westlake, C.; Cole, S. P. C. Transmembrane transport of endo-and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol. Rev. 2006, 86, 849-899.
85. Zhang, H.; Xiang, M. L.; Zhao, Y. L.; Wei, Y. Q.; Yang, S. Y. Support vector machine and pharmacophore-based prediction models of multidrug-resistance protein 2 (MRP2) inhibitors. Eur. J. Pharm. Sci. 2009, 36, 451-457.
86. Jemnitz, K.; Heredi-Szabo, K.; Janossy, J.; Ioja, E.; Vereczkey, L.; Krajcsi, P. ABCC2/Abcc2: a multispecific transporter with dominant excretory functions. Drug Metab. Rev. 2010, 42, 402-436.
87. Eckford, P. D. W.; Sharom, F. J. ABC efflux pump-based resistance to chemotherapy drugs. Chem. Rev. 2009, 109, 2989-3011.
88. Ryu, S.; Kawabe, T.; Nada, S.; Yamaguchi, A. Identification of basic residues involved in drug export function of human multidrug resistance-associated protein 2. J. Biol. Chem. 2000, 275, 39617-39624.
89. Keitel, V.; Kartenbeck, J.; Nies, A. T.; Spring, H.; Brom, M.; Keppler, D. Impaired protein maturation of the conjugate export pump multidrug resistance protein 2 as a consequence of a deletion mutation in Dubin-Johnson syndrome. Hepatology 2000, 32, 1317-1328.
90. Chu, X. Y.; Strauss, J. R.; Mariano, M. A.; Li, J.; Newton, D. J.; Cai, X. X.; Wang, R. W.; Yabut, J.; Hartley, D. P.; Evans, D. C.; Evers, R. Characterization of mice lacking the multidrug resistance protein Mrp2 (Abcc2). J. Pharmacol. Exp. Ther. 2006, 317, 579-589.
91. Jansen, P. L. M.; Peters, W. H.; Lamers, W. H. Hereditary chronic conjugated hyperbilirubinemia in mutant rats caused by defective hepatic anion transport. Hepatology 1985, 5, 573-579.
92. Vlaming, M. L. H.; Pala, Z.; van Esch, A.; Wagenaar, E.; de Waart, D. R.; van de Wetering, K.; van der Kruijssen, C. M. M.; Elferink, R.; van Tellingen, O.; Schinkel, A. H. Functionally overlapping roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate in vivo. Clin. Cancer Res. 2009, 15, 3084-3093.
93. Paulusma, C. C.; Bosma, P. J.; Zaman, G. J. R.; Bakker, C. T. M.; Otter, M.; Scheffer, G. L.; Scheper, R. J.; Borst, P.; Elferink, R. Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. Science 1996, 271, 1126-1128.
94. Ceckova, M.; Vackova, Z.; Radilova, H.; Libra, A.; Buncek, M.; Staud, F. Effect of ABCG2 on cytotoxicity of platinum drugs: interference of EGFP. Toxicol. In Vitro 2008, 22, 1846-1852.
95. Zhou, B.; Gitschier, J. hCTR1: a human gene for copper uptake identified by complementation in yeast. Proc. Natl. Acad. Sci. USA 1997, 94, 7481-7486.
96. Lee, J.; Pena, M. M. O.; Nose, Y.; Thiele, D. J. Biochemical characterization of the human copper transporter 1. J. Biol. Chem. 2002, 277, 4380-4387.
97. Holzer, A. K.; Varki, N. M.; Le, Q. T.; Gibson, M. A.; Naredi, P.; Howell, S. B. Expression of the human copper influx transporter 1 in normal and malignant human tissues. J. Histochem. Cytochem. 2006, 54, 1041-1049.
98. Lee, J.; Prohaska, J. R.; Dagenais, S. L.; Glover, T. W.; Thiele, D. J. Isolation of a murine copper transporter gene, tissue specific expression and functional complementation of a yeast copper transport mutant. Gene 2000, 254, 87-96.
99. Kuo, Y. M.; Zhou, B.; Cosco, D.; Gitschier, J. The copper transporter CTR1 provides an essential function in mammalian embryonic development. Proc. Natl. Acad. Sci. USA 2001, 98, 6836-6841.
100. Lee, J.; Prohaska, J. R.; Thiele, D. J. Essential role for mammalian copper transporter Ctr1 in copper homeostasis and embryonic development. Proc. Natl. Acad. Sci. USA 2001, 98, 6842-6847.
101. Bertinato, J.; Swist, E.; Plouffe, L. J.; Brooks, S. P. J.; L'Abbe, M. R. Ctr2 is partially localized to the plasma membrane and stimulates copper uptake in COS-7 cells. Biochem. J. 2008, 409, 731-740.
102. Van den Berghe, P. V. E.; Folmer, D. E.; Malingre, H. E. M.; Van Beurden, E.; Klomp, A. E. M.; De Sluis, B. V.; Merkx, M.; Berger, R.; Klomp, L. W. J. Human copper transporter 2 is localized in late endosomes and lysosomes and facilitates cellular copper uptake. Biochem. J. 2007, 407, 49-59.
103. Rees, E. M.; Lee, J.; Thiele, D. J. Mobilization of intracellular copper stores by the Ctr2 vacuolar copper transporter. J. Biol. Chem. 2004, 279, 54221-54229.
104. La Fontaine, S.; Ackland, M. L.; Mercer, J. F. Mammalian coppertransporting P-type ATPases, ATP7A and ATP7B: emerging roles. Int. J. Biochem. Cell Biol. 2010, 42, 206-209.
105. Lutsenko, S.; Barnes, N. L.; Bartee, M. Y.; Dmitriev, O. Y. Function and regulation of human copper-transporting ATPases. Physiol. Rev. 2007, 87, 1011-1046.
106. Guo, Y.; Nyasae, L.; Braiterman, L. T.; Hubbard, A. L. NH2-terminal signals in ATP7B Cu-ATPase mediate its Cu-dependent anterograde traffic in polarized hepatic cells. Am. J. Physiol-Gastr. L. 2005, 289, G904-G916.
107. Petris, M. J.; Strausak, D.; Mercer, J. F. B. The Menkes copper transporter is required for the activation of tyrosinase. Hum. Mol. Gen. 2000, 9, 2845-2851.
108. Waggoner, D. J.; Bartnikas, T. B.; Gitlin, J. D. The role of copper in neurodegenerative disease. Neurobiol. Dis. 1999, 6, 221-230.
109. La Fontaine, S.; Firth, S. D.; Lockhart, P. J.; Brooks, H.; Camakaris, J.; Mercer, J. F. B. Intracellular localization and loss of copper responsiveness of Mnk, the murine homologue of the Menkes protein, in cells from blotchy (Mo-blo) and brindled (Mobr) mouse mutants. Hum. Mol. Gen. 1999, 8, 1069-1075.
110. Wu, J. S.; Forbes, J. R.; Chen, H. S.; Cox, D. W. The LEC rat has a deletion in the copper transporting ATPase gene homologus to the Wilson disease gene. Nat. Genet. 1994, 7, 541-545.
111. Rauch, H.; Wells, A. J. The toxic milk mutation, tx, which results in a condition resembling Wilson disease in humans, is linked to mouse chromosome 8. Genomics 1995, 29, 551-552.
112. La Fontaine, S.; Firth, S. D.; Camakaris, J.; Englezou, A.; Theophilos, M. B.; Petris, M. J.; Howie, M.; Lockhart, P. J.; Greenough, M.; Brooks, H.; Reddel, R. R.; Mercer, J. F. B. Correction of the copper transport defect of Menkes patient fibroblasts by expression of the Menkes and Wilson ATPases. J. Biol. Chem. 1998, 273, 31375-31380.
113. Ciarimboli, G. Organic cation transporters. Xenobiotica 2008, 38, 936-971.
114. Koepsell, H.; Lips, K.; Volk, C. Polyspecific organic cation transporters: Structure, function, physiological roles, and biopharmaceutical implications. Pharmaceut. Res. 2007, 24, 1227-1251.
115. Wright, S. H.; Dantzler, W. H. Molecular and cellular physiology of renal organic cation and anion transport. Physiol. Rev. 2004, 84, 987-1049.
116. Keopsell, H.; Endou, H. The SLC22 drug trasnporter family. Pflug. Arch. 2004, 447, 666-676.
117. Koepsell, H. Substrate recognition and translocation by polyspecific organic cation transporters. Biol. Chem. 2011, 392, 95-101.
118. Wang, Y.; Ye, J.; Ganapathy, V.; Longo, N. Mutations in the organic cation/carnitine transporter OCTN2 in primary carnitine deficiency. Proc. Natl. Acad. Sci. USA 1999, 96, 2356-2360.
119. Palmieri, O.; Latiano, A.; Valvano, R.; D'Incà, R.; Vecchi, M.; Sturniolo, G.C.; Saibeni, S.; Peyvandi, F.; Bossa, F.; Zagaria, C.; Andriulli, A.; Devoto, M.; Annese, V. Variants of OCTN1-2 cation transporter genes are associated with both Crohn's disease and ulcerative colitis. Aliment. Pharmacol. Ther. 2006, 23, 497-506.
120. Takane, H.; Shikata, E.; Otsubo, K.; Higuchi, S.; Ieiri, I. Polymorphism in human organic cation transporters and metformin action. Pharmacogenomics 2008, 9, 415-422.
121. Franke, R. M.; Kosloske, A. M.; Lancaster, C. S.; Filipski, K. K.; Hu, C. X.; Zolk, O.; Mathijssen, R.H.; Sparreboom, A. Influence of Oct1/Oct2-deficiency on cisplatin-Induced changes in urinary Nacetyl-beta-D-glucosaminidase. Clin. Cancer Res. 2010, 16, 4198-4206.
122. Zwart, R.; Verhaagh, S.; Buitelaar, M.; Popp-Snijders, C.; Barlow, D. P. Impaired activity of the extraneuronal monoamine transporter system known as uptake-2 in Orct3/Slc22a3-deficient mice. Mol. Cell Biol. 2001, 21, 4188-4196.
123. Yokogawa, K.; Yonekawa, M.; Tamai, I.; Ohashi, R.; Tatsumi, Y.; Higashi, Y.; Nomura, M.; Hashimoto, N.; Nikaido, H.; Hayakawa, J. Loss of wild-type carrier-mediated L-carnitine transport activity in hepatocytes of juvenile visceral steatosis mice. Hepatology 1999, 30, 997-1001.
124. Kato, Y.; Kubo, Y.; Iwata, D.; Kato, S.; Sudo, T.; Sugiura, T.; Kagaya, T.; Wakayama, T.; Hirayama, A.; Sugimoto, M.; Sugihara, K.; Kaneko, S.; Soga, T.; Asano, M.; Tomita, M.; Matsui, T.; Wada, M.; Tsuji, A. Gene knockout and metabolome analysis of carnitine/organic cation transporter OCTN1. Pharm. Res. 2010, 27, 832-840.
125. Pan, B. F.; Sweet, D. H.; Pritchard, J. B.; Chen, R.; Nelson, J. A. A transfected cell model for the renal toxin transporter, rOCT2. Toxicol. Sci. 1999, 47, 181-186.
126. Nishihara, K.; Masuda, S.; Ji, L.; Katsura, T.; Inui, K. I. Pharmacokinetic significance of luminal multidrug and toxin extrusion 1 in chronic renal failure rats. Biochem. Pharmacol. 2007, 73, 1482-1490.
127. Otsuka, M.; Matsumoto, T.; Morimoto, R.; Arioka, S.; Omote, H.; Moriyama, Y. A human transporter protein that mediates the final excretion step for toxic organic cations. Proc. Natl. Acad. Sci. USA 2005, 102, 17923-17928.
128. Masuda, S.; Terada, T.; Yonezawa, A.; Tanihara, Y.; Kishimoto, K.; Katsura, T.; Ogawa, O.; Inui, K. Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J. Am. Soc. Nephrol. 2006, 17, 2127-2135.
129. Terada, T.; Inui, K.I. Physiological and pharmacokinetic roles of H+/organic cation antiporters (MATE/SLC47A). Biochem. Pharmacol. 2008, 75, 1689-1696.
130. Tsuda M, Terada T, Mizuno T, Katsura T, Shimakura J, Inui K. Targeted disruption of the multidrug and toxin extrusion 1 (Mate1) gene in mice reduces renal secretion fo metformin. Mol. Pharmacol. 2009, 75, 1280-1286.
131. Jandial, D. D.; Farshchi-Heydari, S.; Larson, C. A.; Elliott, G. I.; Wrasidlo, W. J.; Howell, S. B. Enhanced delivery of cisplatin to intraperitoneal ovarian carcinomas mediated by the effects of bortezomib on the human copper transporter 1. Clin. Cancer Res. 2009, 15, 553-560.
132. Blair, B. G.; Larson, C. A.; Adams, P. L.; Abada, P. B.; Pesce, C. E.; Safaei, R.; Howell, S. B. Copper transporter 2 regulates endocytosis and controls tumor growth and sensitivity to cisplatin in vivo. Mol. Pharmacol. 2011, 79, 157-166.
133. Katano, K.; Kondo, A.; Safaei, R.; Holzer, A.; Samimi, G.; Mishima, M.; Kuo, Y. M.; Rochdi, M.; Howell, S. B. Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. Cancer Res. 2002, 62, 6559-6565.
134. Safaei, R.; Katano, K.; Samimi, G.; Naerdemann, W.; Stevenson, J. L.; Rochdi, M.; Howell, S. B. Cross-resistance to cisplatin in cells with acquired resistance to copper. Cancer Chemother. Pharmacol. 2004, 53, 239-246.
135. Yoshizawa, K.; Nozaki, S.; Kitahara, H.; Ohara, T.; Kato, K.; Kawashiri, S.; Yamamoto, E. Copper efflux transporter (ATP7B) contributes to the acquisition of cisplatin-resistance in human oral squamous cell lines. Onco. l Rep. 2007, 18, 987-991.
136. Nakagawa, T.; Inoue, Y.; Kodama, H.; Yamazaki, H.; Kawai, K.; Suemizu, H.; Masuda, R.; Iwazaki, M.; Yamada, S.; Ueyama, Y.; Inoue, H.; Nakamura, M. Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) correlates with cisplatin resistance in human non-small cell lung cancer xenografts. Oncol. Rep. 2008, 20, 265-270.
137. Taniguchi, K.; Wada, M.; Kohno, K.; Nakamura, T.; Kawabe, T.; Kawakami, M.; Kagotani, K.; Okumura, K.; Akiyama, S.; Kuwano, M. A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res. 1996, 56, 4124-4129.
138. Kool, M.; de Haas, M.; Scheffer, G. L.; Scheper, R. J.; van Eijk, M. J.; Juijn, J. A.; Baas, F.; Borst, P. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res. 1997, 57, 3537-3547.
139. Liedert, B.; Materna, V.; Schadendorf, D.; Thomale, J.; Lage, H. Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin. J. Invest. Dermatol. 2003, 121, 172-176.
140. Surowiak, P.; Materna, V.; Kaplenko, I.; Spaczynski, M.; Dolinska-Krajewska, B.; Gebarowska, E.; Dietel, M.; Zabel, M.; Lage, H. ABCC2 (MRP2, cMOAT) can be localized in the nuclear membrane of ovarian carcinomas and correlates with resistance to cisplatin and clinical outcome. Clin. Cancer Res. 2006, 12, 7149-7158.
141. Holzer, A. K.; Howell, S. B. The internalization and degradation of human copper transporter 1 following cisplatin exposure. Cancer Res. 2006, 66, 10944-10952.
142. William, W. N. J.; Glisson, B. S. Novel strategies for the treatment of small-cell lung carcinoma. Nat. Rev. Clin. Oncol. 2011, 8, 611-619.
143. Fujii, R.; Mutoh, M.; Niwa, K.; Yamada, K.; Aikou, T.; Nakagawa, M.; Kuwano, M.; Akiyama, S. Active efflux system for cisplatin in cisplatin-resistant human KB cells. Jpn. J. Cancer Res. 1994, 85, 426-433.
144. Nakagawa, M.; Nomura, Y.; Kobno, K.; Ono, M.; Mizoguchi, H.; Ogata, J.; Kuwano, M. Reduction of drug accumulation in cisplatin-resistant variants of human prostatic cancer PC-3 cell line. J. Urol. 1993, 150, 1970-1973.
145. Kotoh, S.; Naito, S.; Yokomizo, A.; Kumazawa, J.; Asakuno, K.; Kohno, K.; Kuwano, M. Increased expression of DNA topoisomerase I gene and collateral sensitivity to camptothecin in human cisplatin-resistant bladder cancer cells. Cancer Res. 1994, 54, 3248-3252.
146. Arany, I.; Safirstein, R. L. Cisplatin nephrotoxicity. Semin. Nephrol. 2003, 23, 460-464.
147. Blakley, B. W.; Myers, S. F. Patterns of hearing loss resulting from cis-platinum therapy. Otolaryngol. Head Neck Surg. 1993, 109, 385-391.
148. Mollman, J. E. Cisplatin neurotoxicity. N. Engl. J. Med. 1990, 322, 126-127.
149. McKeage, M. J. Comparative adverse effect profiles of platinum drugs. Drug Safety 1995, 13, 228-244.
150. Endo, T.; Kimura, O.; Sakata, M. Carrier-mediated uptake of cisplatin by the OK renal epithelial cell line. Toxicology 2000, 146, 187-195.
151. Kolb, R. J.; Ghazi, A. M.; Barfuss, D. W. Inhibition of basolateral transport and cellular accumulation of cDDP and N-acetyl-Lcysteine-cDDP by TEA and PAH in the renal proximal tubule. Cancer Chemother. Pharmacol. 2003, 51, 132-138.
152. Ludwig, T.; Riethmuller, C.; Gekle, M.; Schwerdt, G.; Oberleithner, H. Nephrotoxicity of platinum complexes is related to basolateral organic cation transport. Kidney Intl. 2004, 66, 196-202.
153. Filipski, K. K.; Mathijssen, R. H.; Mikkelsen, T.S.; Schinkel, A.H.; Sparreboom, A. Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin. Pharmacol. Therap. 2009, 86, 396-402.
154. Ciarimboli, G.; Deuster, D.; Knief, A.; Sperling, M.; Holtkamp, M.; Edemir, B.; Pavenstadt, H.; Lanvers-Kaminsky, C.; Zehnhoff-Dinnesen, A. A.; Schinkel, A. H.; Koepsell, H.; Jurgens, H.; Schlatter, E. Organic cation transporter 2 mediates cisplatininduced oto-and nephrotoxicity and is a target for protective interventions. Am. J. Pathol. 2010, 176, 1169-1180.
155. Lancaster, C. S.; Hu, C. X.; Franke, R. M.; Filipski, K. K.; Orwick, S. J.; Chen, Z. Y.; Zuo, Z. L.; Loos, W. J.; Sparreboom, A. Cisplatin-induced downregulation of OCTN2 affects carnitine wasting. Clin. Cancer Res. 2010, 16, 4789-4799.
156. Liu, J. J.; Jamieson, S. M.; Subramaniam, J.; Ip, V.; Jong, N. N.; Mercer, J. F. B.; McKeage, M. J. Neuronal expression of copper transporter 1 in rat dorsal root ganglia: association with platinum neurotoxicity. Cancer Chemother. Pharmacol. 2009, 64, 847-856.
157. Ip, V.; Liu, J. J.; Mercer, J. F. B.; McKeage, M. J. Differential expression of ATP7A, ATP7B and CTR1 in adult rat dorsal root ganglion tissue. Mol Pain 2010, 6, 1-9 (open access).
158. Balayssac, D.; Cayre, A.; Authier, N.; Ling, B.; Maublant, J.; Eschalier, A.; Penault-Llorca, F.; Coudore, F. Involvement of the multidrug resistance transporters in cisplatin-induced neuropathy in rats: comparison with the chronic constriction injury model and monoarthritic rats. Eur. J. Pharmacol. 2006, 544, 49-57.
159. Ichimura, T.; Hung, C. C.; Yang, S. A.; Stevens, J. L.; Bonventre, J. V. Kidney injury molecule-1: a tissue and urinary biomarker for nephrotoxicant-induced renal injury. Am. J. Physiol. Renal Physiol. 2004, 286, F552-F563.
160. Gonzales-Vitale, J. C.; Hayes, D. M.; Cvitkovic, E.; Sternberg, S. S. The renal pathology in clinical trials of cis-platinum (II) diamminedichloride. Cancer 1977, 39, 1362-1371.
161. Motohashi, H.; Sakurai, Y.; Saito, H.; Masuda, S.; Urakami, Y.; Goto, M.; Fukatsu, A.; Ogawa, O.; Inui, K. Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J. Am. Soc. Nephrol. 2002, 13, 866-874.
162. Inui, K. Cellular and molecular aspects of drug transport in the kidney. Kidney Intl. 2000, 58, 925-943.
163. Urakami, Y.; Okuda, M.; Masuda, S.; Saito, H.; Inui, K. I. Functional characteristics and membrane localization of rat multispecific organic cation transporters, OCT1 and OCT2, mediating tubular secretion of cationic drugs. J. Pharmacol. Exp. Ther. 1998, 287, 800-805.
164. Urakami, Y.; Nakamura, N.; Takahashi, K.; Okuda, M.; Saito, H.; Hashimoto, Y. Gender differences in expression of organic cation transporter OCT2 in rat kidney. FEBS Lett. 1999, 461, 339-342.
165. Hu, S.; Franke, R. M.; Filipski, K. K.; Hu, C.; Orwick, S. J.; de Bruijn, E. A.; Burger, H.; Baker, S. D.; Sparreboom, A. Interaction of imatinib with human organic ion carriers. Clin. Cancer Res. 2008, 14, 3141-3148.
166. Li, Y.; Womerc, R. B.; Silbera, J. H. Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose. Eur. J. Cancer 2003, 40, 2445-2451.
167. Ramírez-Camacho, R.; García-Berrocal, J. R.; Trinidad, A.; Verdaguer, J. M.; Nevado, J. Blebs in inner and outer hair cells: a pathophysiological hypothesis. J. Laryngol. Otol. 2008, 1151-1155.
168. Cardinaal, R. M.; de Groot, J. C.; Huizing, E. H.; Veldman, J. E.; Smoorenburg, G. F. Dose-dependent effect of 8-day cis-platin administration upon the morphology of the albino guinea pig cochlea. Hear Res. 2000, 144, 135-146.
169. Thompson, S. W.; Davis, L. E.; Kornfeld, M.; Hilgers, R. D.; Standefer, J. C. Cisplatin neuropathy: clinical, electrophysiologic, morphologic, and toxicologic studies. Cancer 1984, 54, 1269-1279.
170. Holmes, J.; Stanko, J.; Varchenko, M.; Ding, H.; Madden, V. J.; Bagnell, C. R.; Wyrick, S. D.; Chaney, S. G. Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a Wistar rat model. Toxicol. Sci. 1998, 46, 342-351.
171. Jamieson, S. M.; Liu, J.; Connor, B.; McKeage, M. J. Oxaliplatin causes selective atrophy of a subpopulation of dorsal root ganglion neurons without inducing cell loss. Cancer Chemother. Pharmacol. 2005, 56, 391-399.
172. Nakayama, K.; Kanzaki, A.; Ogawa, K.; Miyazaki, K.; Neamati, N.; Takebayashi, Y. Copper-transporting P-type adenosine triphosphatase (ATP7B) as a cisplatin based chemoresistance marker in ovarian carcinoma: Comparative analysis with expression of MDR1, MRP1, MRP2, LRP and BCRP. Intl. J. Cancer 2002, 101, 488-495.
173. Miyashita, H.; Nitta, Y.; Mori, S.; Kanzaki, A.; Nakayama, K.; Terada, K.; Sugiyama, T.; Kawamura, H.; Sato, A.; Morikawa, H.; Motegi, K.; Takebayashi, Y. Expression of copper-transporting Ptype adenosine triphosphatase (ATP7B) as a chemoresistance marker in human oral squamous cell carcinoma treated with cisplatin. Oral Oncol. 2003, 39, 157-162.
174. Higashimoto, M.; kanzaki, A.; Shimakawa, T. Expression of copper-transporting P-type adenosine triphosphatase in human esophargeal carcinoma. Int. J. Mol. Med. 2003, 11, 337-341.
175. Nakayama, K.; Kanzaki, A.; Terada, K.; Mutoh, M.; Ogawa, K.; Sugiyama, T.; Takenoshita, S.; Itoh, K.; Yaegashi, N.; Miyazaki, K.; Neamati, N.; Takebayashi, Y. Prognostic value of the Cutransporting ATPase in ovarian carcinoma patients receiving cisplatin-based chemotherapy. Clin. Cancer Res. 2004, 10, 2804-2811.
176. Martinez-Balibrea, E.; Martinez-Cardus, A.; Musulen, E.; Gines, A.; Manzano, J. L.; Aranda, E.; Plasencia, C.; Neamati, N.; Abad, A. Increased levels of copper efflux transporter ATP7B are associated with poor outcome in colorectal cancer patients receiving oxaliplatin-based chemotherapy. Intl. J. Cancer 2009, 124, 2905-2910.
177. Samimi, G.; Varki, N. M.; Wilczynski, S.; Safaei, R.; Alberts, D. S.; Howell, S. B. Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients. Clin. Cancer Res. 2003, 9, 5853-5859.
178. Lee, Y. Y.; Choi, C. H.; Do, I. G.; Song, S. Y.; Lee, W.; Park, H. S.; Song, T. J.; Kim, M. K.; Kim, T. J.; Lee, J. W.; Bae, D. S.; Kim, B. G. Prognostic value of the copper transporters, CTR1 and CTR2, in patients with ovarian carcinoma receiving platinum-based chemotherapy. Gynecol. Oncol. 2011, 122, 361-365.
179. Yoh, K.; Ishii, G.; Yokose, T.; Minegishi, Y.; Tsuta, K.; Goto, K.; Nishiwaki, Y.; Kodama, T.; Suga, M.; Ochiai, A. Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer. Clin. Cancer Res. 2004, 10, 1691-1697.
180. Kim, Y. H.; Ishii, G.; Goto, K.; Ota, S.; Kubota, K.; Murata, Y.; Mishima, M.; Saijo, N.; Nishiwaki, Y.; Ochiai, A. Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer. Lung Cancer 2009, 65, 105-111.
181. Ota, S.; Ishii, G.; Goto, K.; Kubota, K.; Kim, Y. H.; Kojika, M.; Murata, Y.; Yamazaki, M.; Nishiwaki, Y.; Eguchi, K.; Ochiai, A. Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy. Lung Cancer 2009, 64, 98-104.
182. Ushijima, R.; Takayama, K.; Izumi, M.; Harada, T.; Horiuchi, Y.; Uchino, J.; Hara, N.; Nakanishi, Y. Immunohistochemical expression of MRP2 and clinical resistance to platinum-based chemotherapy in small cell lung cancer. Anticancer Res. 2007, 27, 4351-4358.
183. Yamasaki, M.; Makino, T.; Masuzawa, T.; Kurokawa, Y.; Miyata, H.; Takiguchi, S.; Nakajima, K.; Fujiwara, Y.; Matsuura, N.; Mori, M.; Doki, Y. Role of multidrug resistance protein 2 (MRP2) in chemoresistance and clinical outcome in oesophageal squamous cell carcinoma. Br. J. Cancer 2011, 104, 707-713.
184. Korita, P. V.; Wakai, T.; Shirai, Y.; Matsuda, Y.; Sakata, J.; Takamura, M.; Yano, M.; Sanpei, A.; Aoyagi, Y.; Hatakeyama, K.; Ajioka, Y. Multidrug resistance-associated protein 2 determines the efficacy of cisplatin in patients with hepatocellular carcinoma. Oncol. Rep. 2010, 23, 965-972.
185. Ohishi, Y.; Oda, Y.; Uchiumi, T.; Kobayashi, H.; Hirakawa, T.; Miyamoto, S.; Kinukawa, N.; Nakano, H.; Kuwano, M.; Tsuneyoshi, M. ATP-binding cassette superfamily transporter gene expression in human primary ovarian carcinoma. Clin. Cancer Res. 2002, 8, 3767-3775.
186. Doyle, L. A.; Yang, W.; Abruzzo, L. V.; Krogmann, T.; Gao, Y.; Rishi, A. K.; Ross, D. D. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. USA 1998, 95, 15665-15670.
187. Maliepaard, M.; Scheffer, G. L.; Faneyte, I. F.; van Gastelen, M. A.; Pijnenborg, A.; Schinkel, A. H.; van de Vijver, M. J.; Scheper, R. J.; Schellens, J. H. M. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res. 2001, 61, 3458-3464.
188. Ni, Z.; Bikadi, Z.; Rosenberg, M. F.; Mao, Q. Structure and function of the human breast cancer resistance protein (BCRP/ABCG2). Current Drug Metab. 2010, 11, 603-617.
189. Robey, R. W.; Polgar, O.; Deeken, J.; To, K. W.; Bates, S. E. ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis. Rev. 2007, 26, 39-57.
190. Keskitalo, J. E.; Pasanen, M. K.; Neuvonen, P. J.; Niemi, M. Different effects of the ABCG2 c.421C > A SNP on the pharmacokinetics of fluvastatin, pravastatin and simastatin. Pharmacogenomics 2009, 10, 1617-1624.
191. Vlaming, M. L. H.; van Esch, A.; Pala, Z.; Wagenaar, E.; van de Wetering, K.; van Tellingen, O.; Schinkel, A. H. Abcc2 (Mrp2), Abcc3 (Mrp3) and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo. Mol. Cancer Ther. 2009, 8, 3350-3359.
192. Graham, M. A.; Lockwood, G. F.; Greenslade, D.; Brienza, S.; Bayssas, M.; Gamelin, E. Clinical pharmacokinetics of oxaliplatin: A critical review. Clin. Cancer Res. 2000, 6, 1205-1218.
193. Masek, V.; Anzenbacherová, E.; Machová, M.; Brabec, V.; Anzenbacher, P. Interaction of antitumor platinum complexes with human liver microsomal cytochromes P450. Anti-cancer Drugs 2009, 20, 305-311.
194. Giacomini, K. M.; Huang, S. M.; Tweedie, D. J.; Benet, L. Z.; Brouwer, K. L. R.; Chu, X. Y.; Dahlin, A.; Evers, R.; Fischer, V.; Hillgren, K. M.; Hoffmaster, K. A.; Ishikawa, T.; Keppler, D.; Kim, R. B.; Lee, C. A.; Niemi, M.; Polli, J. W.; Sugiyama, Y.; Swaan, P. W.; Ware, J. A.; Wright, S. H.; Yee, S. W.; Zamek-Gliszczynski, M. J.; Zhang, L. Membrane transporters in drug development. Nat. Rev. Drug Disc. 2010, 9, 215-236.
195. De Feo, C. J.; Aller, S. G.; Siluvai, G. S.; Blackburn, N. J.; Unger, V. M. Three dimensional structure of the human copper transporter hCTR1. Proc. Natl. Acad. Sci. USA 2009, 106, 4237-4242.
196. Fu, S.; Naing, A.; Fu, C.; Kuo, M. T.; Kurzrock, R. Overcoming platinum resistance through the use of a copper-lowering agent. Mol. Cancer Ther. 2012, OnlineFirst Aril 5, 2012. DOI:10.1158/1538-7163.MCT-11-0864.
197. Lu, J. Triethylenetetramine pharmacology and its clinical applications. Mol. Cancer Ther. 2010, 9, 2458-2467.
198. White, D. L.; Dang, P.; Engler, J.; Frede, A.; Zrim, S.; Osborn, M.; Saunders, V. A.; Manley, P. W.; Hughes, T. P. Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. J. Clin. Oncol. 2010, 28, 2761-2767.
199. Wojnowski, L.; Kulle, B.; Schirmer, M.; Schlüter, G.; Schmidt, A.; Rosenberger, A.; Vonhof, S.; Bickeboller, H.; Toliat, M. R.; Suk, E. T., M; Kruger, A.; Seifert, S.; Kloess, M.; Hahn, H.; Loeffler, M.; Nürnberg, P.; Pfreundschuh, M.; Trumper, L.; Brockmoller, J.; Hasenfuss, G. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 2005, 112, 3754-3762.
200. Tamura, A.; Wakabayashi, K.; Onishi, Y. Re-evaluation and functional classification of non-synonymous single nucleotide polymorphisms of the human ATP-binding cassette transporter ABCG2. Cancer Sci. 2007, 98, 231-239.
201. Choi, M. K.; Song, I. S. Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab. Pharmacokinet. 2008, 23, 243-253.
202. Briz, O.; Serrano, M. A.; Rebollo, N.; Hagenbuch, B.; Meier, P. J.; Koepsell, H.; Marin, J. J. G. Carriers involved in targeting the cytostatic bile acid-cisplatin derivatives cis-diammine-chlorocholylglycinate-platinum(II) and cis-diamminebisursodeoxycholate-platinum(II) toward liver cells. Mol. Pharmacol. 2002, 61, 853-860.
203. Khandani, A. H.; Dunphy, C. H.; Meteesatien, P.; Dufault, D. L.; Ivanovic, M.; Shea, T. C. Glut1 and Glut3 expression in lymphoma and their association with tumor intensity on 18Ffluorodeoxyglucose positron emission tomography. Nucl. Med. Commun. 2009, 30, 594-601.